Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2005-02-08
2005-02-08
Andres, Janet (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S399000, C530S387100, C530S388100, C530S389100, C435S069100
Reexamination Certificate
active
06852839
ABSTRACT:
The present invention provides a purified polynucleotide encoding a novel polypeptide, designated Fhm, which belongs to the TNF gene superfamily; to purified Fhm polypeptide molecules; to antibodies that bind Fhm; to materials comprising such molecules; and to methods of using such molecules.
REFERENCES:
patent: 5489743 (1996-02-01), Robinson et al.
patent: 5843789 (1998-12-01), Nomura et al.
patent: 5863769 (1999-06-01), Young
patent: 6599719 (2003-07-01), Yu et al.
patent: 20020111325 (2002-08-01), Li et al.
patent: 20020150534 (2002-10-01), Yu et al.
patent: 20020150583 (2002-10-01), Gentz et al.
patent: 20030027284 (2003-02-01), Yu et al.
patent: 20030129189 (2003-07-01), Yu et al.
patent: 20030198640 (2003-10-01), Yu et al.
patent: 20040013664 (2004-01-01), Gentz et al.
patent: 19809978 (1999-09-01), None
patent: 0861850 (1998-09-01), None
patent: WO 9614328 (1996-05-01), None
patent: WO 9637609 (1996-11-01), None
patent: WO 9830694 (1998-07-01), None
patent: WO 9904001 (1999-01-01), None
patent: WO 9906426 (1999-02-01), None
patent: WO 9907738 (1999-02-01), None
patent: WO 9911791 (1999-03-01), None
patent: WO 9914330 (1999-03-01), None
patent: WO 9920758 (1999-04-01), None
patent: WO 9923105 (1999-05-01), None
patent: WO 9923105 (1999-05-01), None
patent: WO 9926977 (1999-06-01), None
patent: WO 9931128 (1999-06-01), None
patent: WO 9935268 (1999-07-01), None
patent: WO 9950413 (1999-10-01), None
patent: WO 9951744 (1999-10-01), None
patent: WO 0008139 (2000-02-01), None
patent: WO 0018800 (2000-04-01), None
Bamias et al., Expression, Localization, and Functional Activity of TL1A, a Novel Th1-Polarizing cytokine in Inflammatory Bowel Disease, Journal of Immunology, 171:4868-4874, (2003).
Chew et al., “A Novel Secreted Splice Variant of Vascular Endothelial Cell Growth Inhibitor,” FASEB Journal, 16:742-744 (May 2002).
Chen et al., “Quantification and Detection of DcR3, a Decoy Receptor in TNFR Family,” Journal of Immunological Methods 285:63-70, (2004).
Connolly et al., “In Vivo Inhibition of Fas Ligand-Mediated Killing by TR6, a Fas Ligand Decoy Receptor,” J. Pharmacology and Experimental Therapeutics, 298(1):25-33, (2001).
Gill et al., “Differential Expression of LIGHT and its Receptors in Human Placental Villi and Amniochorion Membranes,” American Journal of Pathology, 161(6):2011-2017, (Dec. 2002).
Hsu et al., “Enhanced Adhesion of Monocytes Via Reverse Signaling Triggered by Decoy Receptor 3,” Experimental Cell Research, 292:241-251, (2004).
Kim et al., “Selective Induction of Tumor Necrosis Receptor factor 6/Decoy Receptor 3 Release by Bacterial Antigens in Human Monocytes and Myeloid Dendritic Cells,” Infection and Immunity, 72(1):89-93, (Jan. 2004).
Migone, et al., TL1A is a TNF-Like Ligand for DR3 and TR6/DcR3 and Functions as a T Cell Costimulator,: Immunity, 16:479-492, (Mar. 2002).
Perry et al., “Characterization of Proximal Colonic Lymphoid Tissue in the Mouse,” The Anatomical Record, 220:305-312 (1988).
Pitti et al., “Genomic Amplification of a Decoy Receptor for Fas Ligand in Lung and Colon Cancer,” Nature, 396:699-703, (Dec. 17, 1998).
Shi et al., “Death Decoy Receptor TR6/DcR3 Inhibits T Cell Chemotaxis In Vitro and In Vivo,” Journal of Immunology, 171:3407-3414, (2003).
Shi et al., “Mouse T Cells Receive Costimulatory Signals from LIGHT, a TNF Family Member,” Immunobiology, 100(9):3279-3286, (Nov. 1, 2002).
Tan et al., “Characterization of a Novel TNF-Like Ligand and Recently Described TNF Ligand and TNF Receptor Superfamily Genes and Their Constitutive and Inducible Expression in Hematopoietic and Non-hematopoietic Cells,” Gene, 204:35-46, (1997).
Wan et al., “A TNF Family Member LIGHT Tranduces Costimulatory Signals into Human T Cells,” Journal of Immunology, 169:6813-6821, (2002).
Wan et al., “DcR3/TR6 Modulates Immune Cell Interactions,” Journal of Cellular Biochemistry , 89:603-612, (2003).
Wang et al., “Cloning, Expression and Biological Activity of VEGI(151), a Non-Vascular endothelial Cell Groth Inhibitor,” ACTA Biochimica et Biophysica Sinica, 32(5):485-489, (2000).
Wen et al., “TL1A-induced NF-KB Activation and c-IAP2 Production Prevent DR3-mediated Apoptosis in TF-1 Cells,”J. Bio Chem., 278(40):39251-39258, (2003).
Wu et al., “Clinical Significance of Detecting Elevated Serum DcR3/TR6/M68 in Malignant Tumor Patients,” Int. J. Cancer, 105:724-732 (2003).
Wu et al., “DcR3/TR6 Effectively Prevents Islet Primary Nonfunction After Transplation,” Diabetes, 52:2279-2286.
Yang et al., “Soluble Decoy Receptor 3 Induces Angiogenesis by neutralization of TL1A, a Cytokine Belonging to Tumor Necrosis Factor Superfamily and Exhibiting Angiostatic Action,” Cancer Research, 64:1122-1129, (Feb. 1, 2004).
Yu et al., “A Newly Identified Member of Tumor Necrosis Factor Receptor Superfamily (TR6) Suppresses LIGHT-Mediated Apoptosis,” Journal of Biological Chemistry, 274(20):13733-13736, (May 14, 1999).
Yu et al., “Modulation of Endothelial Cell Growth Arrest and Apoptosis by Vascular Endothelial Growth Inhibitor,” American Heart Association, Inc., pp. 1161-1167 (2001).
Zhai et al., “Inhibition of Angiogenesis and Breast Cancer Xenograft Tumor Growth by Vegi, a Novel Cytokine of the TNF Superfamily,” Int. J. Cancer, 82:131-136, (1999).
Zhai, et al., “VEGI, a Novel Cytokine of the Tumor Necrosis Factor Family, is an Angiogenesis Inhibitor that Suppresses the Growth of Colon Carcinomas In Vivo,” FASEB J., 13:181-189, (1999).
Zhang et al., “LIGHT Sensitizes IFNy-mediated Apoptosis of MDA-MB-231 Breast Cancer Cells Leading to Down-Regulation of Anti-Apoptosis Bcl-2 Family Members,” Cancer Letters 195:201-210, (2003).
Zhang et al., “Modulation of T-cell Responses to Alloantigens by TR6/DcR3,” Journal of Clinical Investigation, 107(11):1459-1468, (Jun. 2001).
Aderka et al., The Potential Biological and Chemical Significance of the Soluble Tumor Necrosis Factor Receptors,Cytokine & Growth Factor Reviews, 7(3):231-240(1996).
Aggarwal et al., Characterization of Receptors for Tumor Necrosis Factor and their Regulation By γ-Interferon,Nature, 318:665-667(1985).
Ausubel et al., eds., Transfection of DNA Into Eukaryotic Cells inCurrent Protocols in Molecular Biology, Section 9.1.1-9.1.3, John Wiley & Sons, New York 1996.
Baker et al., Transducers of Life and Death: TNF Receptor Superfamily and Associated Proteins,Oncogene, 12(1):1-9(1996).
Beyaert et al.,Tumor Necrosis Factor and Lymphokinesin: Cytokines eds. Anthony Mire-Sluis and Robin Thorpe, Academic Press San Diego CA, 1998.
Browning et al., Lymphotoxin β, a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface,Cell. 72:847-856, (1993).
Fernandez-Botran, Soluble Cytokine Receptors: Their Role In Immunoregulation,FASB J.,5:2567-2574(1991).
Fisher, Production of Antibody in Radioimmunoassay in;Manual of Clinical Immunology,2d Ed. (Rose and Friedman, eds.) Amer. Soc. For Microbiol., Washington, D.C., 1980.
Locksley et al., The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology,Cell, 104:487-501(2001).
Moult, The Current State of the Art In Protein Structure Prediction,Curr. Op. in Biotech.,7(4):422-427(1996).
Naismith et al., Modularity in the TNF-receptor Family,TIBS,23:74-79(1998).
Nophar et al., Soluble Forms of Tumor Necrosis Factor Receptors (TNF-Rs). The cDNA for the Type 1 TNF-R, Cloned Using Amino Acid Sequence Data of its Soluble Form, Encodes both the Cell Surface and a Soluble Form of the Receptor,EMBOJ.,9(10):3269-3278(1990).
Orlinick et al., TNF-Related Ligands and Their Receptors,Cell Signal,10(8): 543-551(1998).
Ouchterlony et al., Immunodiffusion and Immunoelectrophoresis in:Handbook of Experimental Immunologyed: D. Weir, Blackwell, 1973.
Porteu et al., Human Neutrophil Elastase Releases a Ligan
Boyle William James
Hsu Hailing
Wooden Scott Kenneth
Amgen Inc.
Andres Janet
LandOfFree
Fhm, a novel member of the TNF ligand supergene family does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fhm, a novel member of the TNF ligand supergene family, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fhm, a novel member of the TNF ligand supergene family will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3447842